Eyal Arieli
Director/Board Member bei MERCHAVIA HOLDINGS AND INVESTMENTS LTD
Profil
Eyal Arieli is currently working as the Chief Operating Officer & Chief Financial Officer at Precise Bio, Inc. and as an Independent External Director at Merchavia Holdings & Investments Ltd.
He completed his undergraduate degree at The Hebrew University of Jerusalem and his MBA at Bar-Ilan University.
Aktive Positionen von Eyal Arieli
| Unternehmen | Position | Beginn |
|---|---|---|
| MERCHAVIA HOLDINGS AND INVESTMENTS LTD | Director/Board Member | 07.06.2020 |
Precise Bio, Inc.
 Precise Bio, Inc. Pharmaceuticals: MajorHealth Technology Precise Bio, Inc. is a regenerative medicine company that specializes in bio-printed tissues and organs for patients in ophthalmology. The company is based in Winston-Salem, NC. The company's main focus is on developing a bio-printed cornea graft to replace donor corneas. The company is also working on a 3D cardiac tissue "patch" for post myocardial infarction implant to retrieve cardiac muscle viability and functionality. Precise Bio uses an integrated 3D printing and tissue-engineering platform to produce scalable, repeatable bio-fabricated organs from the patients' own cells. The company was founded in 2015 by Anthony Atala, Aryeh Batt, Shay Soker. Aryeh Batt has been the CEO since 2015. | Director of Finance/CFO | - |
Ausbildung von Eyal Arieli
| The Hebrew University of Jerusalem | Undergraduate Degree |
| Bar-Ilan University | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| MERCHAVIA HOLDINGS AND INVESTMENTS LTD | Finance |
| Private Unternehmen | 1 |
|---|---|
Precise Bio, Inc.
Precise Bio, Inc. Pharmaceuticals: MajorHealth Technology Precise Bio, Inc. is a regenerative medicine company that specializes in bio-printed tissues and organs for patients in ophthalmology. The company is based in Winston-Salem, NC. The company's main focus is on developing a bio-printed cornea graft to replace donor corneas. The company is also working on a 3D cardiac tissue "patch" for post myocardial infarction implant to retrieve cardiac muscle viability and functionality. Precise Bio uses an integrated 3D printing and tissue-engineering platform to produce scalable, repeatable bio-fabricated organs from the patients' own cells. The company was founded in 2015 by Anthony Atala, Aryeh Batt, Shay Soker. Aryeh Batt has been the CEO since 2015. | Health Technology |
